Compare BDL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDL | ONCY |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 80.5M |
| IPO Year | 1995 | 2002 |
| Metric | BDL | ONCY |
|---|---|---|
| Price | $46.29 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.14 |
| AVG Volume (30 Days) | 21.4K | ★ 1.0M |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $205,248,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.55 | $0.54 |
| 52 Week High | $52.12 | $1.32 |
| Indicator | BDL | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 22.95 |
| Support Level | $29.36 | N/A |
| Resistance Level | $47.99 | $0.89 |
| Average True Range (ATR) | 1.91 | 0.04 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 73.78 | 12.50 |
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.